Best Stocks Under $3 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $3.00 (3 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. Stardust Power NASDAQ:SDST$0.64 0.00 (-0.39%) As of 09:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Stardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.Market Capitalization$36.76 millionConsensus RatingBuyConsensus Price Target$5.11 (+705.1% Upside)Volume1,484 sharesAverage Volume353,185 sharesToday's Range$0.62▼$0.62 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. Achieve Life Sciences NASDAQ:ACHV$2.20 +0.03 (+1.15%) As of 09:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. More about Achieve Life SciencesMarket Capitalization$76.48 millionP/E Ratio-1.95Consensus RatingBuyConsensus Price Target$15.75 (+614.3% Upside)Volume97,460 sharesAverage Volume180,346 shares3. OS Therapies NYSE:OSTX$1.36 +0.11 (+8.80%) As of 09:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. More about OS TherapiesMarket Capitalization$29.03 millionConsensus RatingBuyConsensus Price Target$18.00 (+1,223.5% Upside)Volume103,829 sharesAverage Volume494,082 sharesToday's Range$1.27▼$1.394. Denison Mines NYSEAMERICAN:DNN$1.34 +0.03 (+1.91%) As of 09:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Denison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. Its flagship project is the Wheeler River uranium project covering an area of approximately 300,000 hectares located in the Athabasca Basin region in northern Saskatchewan. More about Denison MinesMarket Capitalization$1.20 billionP/E Ratio-133.50Consensus RatingBuyConsensus Price Target$3.00 (+124.7% Upside)Volume9,590 sharesAverage Volume54.11 million shares5. Solid Biosciences NASDAQ:SLDB$2.76 +0.06 (+2.03%) As of 09:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. More about Solid BiosciencesMarket Capitalization$212.72 millionP/E Ratio-0.90Consensus RatingBuyConsensus Price Target$15.67 (+467.0% Upside)Volume755 sharesAverage Volume880,693 shares6. Quince Therapeutics NASDAQ:QNCX$1.00 0.00 (0.00%) As of 09:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince TherapeuticsMarket Capitalization$44.00 millionP/E Ratio-0.81Consensus RatingBuyConsensus Price Target$8.00 (+700.0% Upside)Volume68,358 sharesAverage Volume246,612 sharesRemove Ads7. GeoVax Labs NASDAQ:GOVX$0.75 -0.32 (-30.00%) As of 09:09 AM EasternGeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. More about GeoVax LabsMarket Capitalization$10.37 millionP/E Ratio-0.13Consensus RatingBuyConsensus Price Target$12.90 (+1,622.3% Upside)Volume272,150 sharesAverage Volume588,489 shares8. Reviva Pharmaceuticals NASDAQ:RVPH$0.79 +0.01 (+1.53%) As of 09:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva PharmaceuticalsMarket Capitalization$36.88 millionP/E Ratio-0.71Consensus RatingBuyConsensus Price Target$10.00 (+1,169.0% Upside)Volume4,762 sharesAverage Volume1.11 million shares9. Cardiol Therapeutics NASDAQ:CRDL$1.00 -0.03 (-3.01%) As of 09:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More about Cardiol TherapeuticsMarket Capitalization$82.53 millionP/E Ratio-2.56Consensus RatingBuyConsensus Price Target$8.40 (+740.8% Upside)Volume3,010 sharesAverage Volume246,266 shares10. Mereo BioPharma Group NASDAQ:MREO$1.93 -0.02 (-1.18%) As of 09:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. More about Mereo BioPharma GroupMarket Capitalization$300.98 millionP/E Ratio-32.33Consensus RatingBuyConsensus Price Target$7.71 (+304.1% Upside)Volume1.96 million sharesAverage Volume1.05 million shares11. Nkarta NASDAQ:NKTX$1.72 +0.02 (+1.18%) As of 09:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. More about NkartaMarket Capitalization$120.98 millionP/E Ratio-0.91Consensus RatingBuyConsensus Price Target$14.86 (+771.4% Upside)Volume824 sharesAverage Volume1.44 million sharesRemove Ads12. Rezolve AI NASDAQ:RZLV$1.20 +0.06 (+4.91%) As of 09:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rezolve Ai Ltd. operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. More about Rezolve AIMarket Capitalization$207.48 millionConsensus RatingBuyConsensus Price Target$6.00 (+397.9% Upside)Volume485,339 sharesAverage Volume5.06 million sharesToday's Range$1.20▼$1.2013. Immunic NASDAQ:IMUX$0.93 +0.01 (+1.51%) As of 09:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about ImmunicMarket Capitalization$83.84 millionP/E Ratio-0.76Consensus RatingBuyConsensus Price Target$13.20 (+1,316.3% Upside)Volume2,082 sharesAverage Volume620,362 shares14. Lucid Diagnostics NASDAQ:LUCD$1.18 -0.01 (-1.26%) As of 09:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. More about Lucid DiagnosticsMarket Capitalization$105.73 millionP/E Ratio-1.02Consensus RatingBuyConsensus Price Target$3.40 (+188.6% Upside)Volume2,247 sharesAverage Volume433,742 shares15. FibroBiologics NASDAQ:FBLG$1.01 +0.03 (+3.47%) As of 09:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. More about FibroBiologicsMarket Capitalization$37.62 millionP/E Ratio-2.93Consensus RatingBuyConsensus Price Target$13.00 (+1,213.1% Upside)Volume299 sharesAverage Volume281,142 shares16. Electrovaya NASDAQ:ELVA$2.46 -0.02 (-0.81%) As of 09:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Electrovaya Inc engages in the design, development, manufacture, and sale of lithium-ion batteries, battery management systems, and battery-related products for energy storage, clean electric transportation, and other specialized applications in North America. More about ElectrovayaMarket Capitalization$98.66 millionP/E Ratio-61.50Consensus RatingBuyConsensus Price Target$6.10 (+148.0% Upside)Volume18,090 sharesAverage Volume51,025 sharesRemove Ads17. Genelux NASDAQ:GNLX$2.48 +0.02 (+0.81%) As of 09:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. More about GeneluxMarket Capitalization$85.30 millionP/E Ratio-2.59Consensus RatingBuyConsensus Price Target$18.25 (+635.9% Upside)Volume157,625 sharesAverage Volume210,543 shares18. Western Copper & Gold NYSE:WRN$1.20 +0.07 (+6.19%) As of 09:07 AM EasternWestern Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & GoldMarket Capitalization$240 millionP/E Ratio-60.00Consensus RatingBuyConsensus Price Target$4.25 (+254.2% Upside)Volume10,875 sharesAverage Volume304,749 shares19. HIVE Digital Technologies NASDAQ:HIVE$1.50 +0.02 (+1.01%) As of 09:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.HIVE Digital Technologies Ltd. operates as a cryptocurrency mining company in Canada, Sweden, and Iceland. The company engages in the mining and sale of digital currencies, including Ethereum Classic, Bitcoin, and other coins. More about HIVE Digital TechnologiesMarket Capitalization$248.42 millionP/E Ratio-30.00Consensus RatingBuyConsensus Price Target$7.64 (+407.8% Upside)Volume39,771 sharesAverage Volume5.96 million shares20. Orchestra BioMed NASDAQ:OBIO$2.97 -0.01 (-0.34%) As of 09:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. More about Orchestra BioMedMarket Capitalization$116.01 millionP/E Ratio-1.88Consensus RatingBuyConsensus Price Target$15.00 (+405.1% Upside)Volume41,397 sharesAverage Volume85,663 shares21. Ceragon Networks NASDAQ:CRNT$2.10 -0.01 (-0.24%) As of 09:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ceragon Networks Ltd., together with its subsidiaries, provides wireless transport solutions for cellular operators and other wireless service providers in North America, Europe, Africa, the Asia Pacific, the Middle East, India, and Latin America. More about Ceragon NetworksMarket Capitalization$185.67 millionP/E Ratio7.74Consensus RatingBuyConsensus Price Target$6.38 (+204.3% Upside)Volume532 sharesAverage Volume1.03 million shares22. NRx Pharmaceuticals NASDAQ:NRXP$2.06 +0.04 (+1.72%) As of 09:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. More about NRx PharmaceuticalsMarket Capitalization$34.93 millionP/E Ratio-0.96Consensus RatingBuyConsensus Price Target$28.25 (+1,268.0% Upside)Volume1,985 sharesAverage Volume444,990 shares23. Perspective Therapeutics NYSE:CATX$2.08 +0.03 (+1.46%) As of 09:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. More about Perspective TherapeuticsMarket Capitalization$154.03 millionConsensus RatingBuyConsensus Price Target$12.75 (+513.0% Upside)Volume891 sharesAverage Volume826,331 sharesToday's Range$2.15▼$2.1524. ProQR Therapeutics NASDAQ:PRQR$1.17 +0.05 (+4.46%) As of 09:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. More about ProQR TherapeuticsMarket Capitalization$122.57 millionP/E Ratio-3.64Consensus RatingBuyConsensus Price Target$9.50 (+712.0% Upside)Volume989,632 sharesAverage Volume578,738 shares25. Gain Therapeutics NASDAQ:GANX$1.82 -0.05 (-2.89%) As of 09:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. More about Gain TherapeuticsMarket Capitalization$51.27 millionP/E Ratio-1.68Consensus RatingBuyConsensus Price Target$8.20 (+353.0% Upside)Volume7,130 sharesAverage Volume289,387 shares More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft: A Blend of Growth and Value Amid Tariff Concerns Why NVIDIA Stock Could Soar Despite Wall Street Downgrades Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold Don’t Fear, New Highs for Fastenal Will Soon Be Here 3 High-Yield Dividend Stocks Trading at a Discount Robinhood Strategies Could Be a Game-Changer for Young Investors MarketBeat Week in Review — 04/07 - 04/11 Is BlackRock Signaling a Market Rally Despite New Tariffs? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
